These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17249245)

  • 1. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs.
    Schang LM; St Vincent MR; Lacasse JJ
    Antivir Chem Chemother; 2006; 17(6):293-320. PubMed ID: 17249245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular proteins (cyclin dependent kinases) as potential targets for antiviral drugs.
    Schang LM
    Antivir Chem Chemother; 2001; 12 Suppl 1():157-78. PubMed ID: 11594683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins.
    Schang LM; Bantly A; Knockaert M; Shaheen F; Meijer L; Malim MH; Gray NS; Schaffer PA
    J Virol; 2002 Aug; 76(15):7874-82. PubMed ID: 12097601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Herpes simplex viruses in antiviral drug discovery.
    Schang LM
    Curr Pharm Des; 2006; 12(11):1357-70. PubMed ID: 16611120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent kinases as cellular targets for antiviral drugs.
    Schang LM
    J Antimicrob Chemother; 2002 Dec; 50(6):779-92. PubMed ID: 12460995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances on cyclin-dependent kinases (CDKs) as novel targets for antiviral drugs.
    Schang LM
    Curr Drug Targets Infect Disord; 2005 Mar; 5(1):29-37. PubMed ID: 15777196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication.
    Schang LM
    Biochim Biophys Acta; 2004 Mar; 1697(1-2):197-209. PubMed ID: 15023361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors.
    Diwan P; Lacasse JJ; Schang LM
    J Virol; 2004 Sep; 78(17):9352-65. PubMed ID: 15308730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis.
    Moffat JF; McMichael MA; Leisenfelder SA; Taylor SL
    Biochim Biophys Acta; 2004 Mar; 1697(1-2):225-31. PubMed ID: 15023363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral drugs that target cellular proteins may play major roles in combating HIV resistance.
    Provencher VM; Coccaro E; Lacasse JJ; Schang LM
    Curr Pharm Des; 2004; 10(32):4081-101. PubMed ID: 15579090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological cyclin-dependent kinase inhibitors as HIV-1 antiviral therapeutics.
    de la Fuente C; Maddukuri A; Kehn K; Baylor SY; Deng L; Pumfery A; Kashanchi F
    Curr HIV Res; 2003 Apr; 1(2):131-52. PubMed ID: 15043199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral drug resistance and helicase-primase inhibitors of herpes simplex virus.
    Field HJ; Biswas S
    Drug Resist Updat; 2011 Feb; 14(1):45-51. PubMed ID: 21183396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
    Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
    J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of the antiviral activities of pharmacologic cyclin-dependent kinase inhibitors: from basic to applied science.
    Schang LM
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):145-9. PubMed ID: 15918771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-Oxo-4,7-dihydrothieno[2,3-b]pyridines as non-nucleoside inhibitors of human cytomegalovirus and related herpesvirus polymerases.
    Schnute ME; Cudahy MM; Brideau RJ; Homa FL; Hopkins TA; Knechtel ML; Oien NL; Pitts TW; Poorman RA; Wathen MW; Wieber JL
    J Med Chem; 2005 Sep; 48(18):5794-804. PubMed ID: 16134946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cdk inhibitory nucleoside analogs prevent transcription from viral genomes.
    Schang LM; Coccaro E; Lacasse JJ
    Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):829-37. PubMed ID: 16248044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential use of pharmacological cyclin-dependent kinase inhibitors as anti-HIV therapeutics.
    Pumfery A; de la Fuente C; Berro R; Nekhai S; Kashanchi F; Chao SH
    Curr Pharm Des; 2006; 12(16):1949-61. PubMed ID: 16787240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological activities of new carbaacyclonucleosides and 1'-oxaacyclonucleosides related to clitocine.
    Bacchelli C; Condom R; Patino N; Aubertin AM
    Nucleosides Nucleotides Nucleic Acids; 2000 Mar; 19(3):567-84. PubMed ID: 10843493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral activities against HSV-1, HCMV, and HIV-1 of rhamnan sulfate from Monostroma latissimum.
    Lee JB; Hayashi K; Hayashi T; Sankawa U; Maeda M
    Planta Med; 1999 Jun; 65(5):439-41. PubMed ID: 10418331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-targeted drug candidate with dual anti-HIV and anti-HSV activity.
    Balzarini J; Andrei G; Balestra E; Huskens D; Vanpouille C; Introini A; Zicari S; Liekens S; Snoeck R; Holý A; Perno CF; Margolis L; Schols D
    PLoS Pathog; 2013; 9(7):e1003456. PubMed ID: 23935482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.